Long-Term Survival Of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma Treated With Second-Line Axitinib In A Multicenter Phase Ii Study.

Ilya Tsimafeyeu,Pavel S. Borisov,Andrey Semenov,Roman Leonenkov,Olga Novikova,Sergey Gamayunov,Nadezhda Mikhailova,Anastasia Bondarenko,Ahmed Abdelgafur

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览4

暂无评分

摘要

332Background: Tyrosine kinase inhibitors remain possible treatment options in favorable risk patients newly diagnosed with metastatic renal cell carcinoma (mRCC). In phase II study (FavorAx), axit...

查看译文

关键词

Treatment,Renal Cell Carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要